SCHEMBL15769772

SCHEMBL15769772

Cc1ccc(Nc2ncc(F)c(N(C)[C@H]3CCCN4CCCC[C@H]34)n2)cc1C#N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.39
AXL P30530 1/20 0.38
LCK P06239 2/20 0.38
JAK3 P52333 2/20 0.38
PAK1 Q13153 5/20 0.38
FYN P06241 2/20 0.38
YES1 P07947 1/20 0.38
LYN P07948 1/20 0.38
SRC P12931 1/20 0.38
PRKCQ Q04759 1/20 0.38
PAK2 Q13177 1/20 0.38
CDK1 P06493 3/20 0.36
CDK4 P11802 3/20 0.36
CDK2 P24941 2/20 0.36
CSF1R P07333 2/20 0.36
CDK6 Q00534 2/20 0.36
CCND1 P24385 2/20 0.36
PIK3CD O00329 1/20 0.36
PRKAB2 O43741 1/20 0.36
NUAK1 O60285 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15769548 0.92 CDK1 (0.40) GRM5LCKJAK3FYNCDK1
SCHEMBL15770097 0.92 JAK3 (0.45) GRM5AXLLCKJAK3FYN
SCHEMBL15769287 0.90 GRM5 (0.38) GRM5AXLLCKJAK3PAK1
SCHEMBL15769749 0.90 JAK3 (0.48) LCKJAK3
SCHEMBL15769401 0.90 JAK2 (0.38) AXLLCKJAK3PAK1FYN
SCHEMBL15770094 0.90 JAK3 (0.38) GRM5AXLLCKJAK3PAK1
SCHEMBL15769154 0.88 CDK1 (0.41) LCKJAK3FYNCDK1CDK4
SCHEMBL15769281 0.85 SYK (0.51) GRM5CDK1CDK4CDK2CCNT1
SCHEMBL15769468 0.84 JAK3 (0.45) AXLLCKJAK3FYNCDK1
SCHEMBL15769429 0.83 JAK3 (0.45) LCKJAK3FYNCDK1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP claimed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US claimed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US claimed
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP disclosed
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2015-10-29 US disclosed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB GRM5 3706/4885AXL 3738/4885LCK 213/4885
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB GRM5 3706/4885AXL 3738/4885LCK 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.